2014年12月11日讯/生物谷BIOON--法国Pierre Fabre最近日子很不好过，不仅R&D部门产能低下，而且法国地区的销售还遭受了降价的冲击。
因此Pierre Fabre决定缩减制药部门的研发，而把更多的资源投入到消费者保健品、化妆品领域。结果是Pierre Fabre决定2016年前在制药部门裁员551人，此次裁员主要波及法国地区，涉及到的岗位主要是研发和销售。
与销售相比，研发部门的裁员更多一些，共要裁员272名，而其中255名都在法国。另外销售部门将裁员279名，其余是巴塞罗那的一个研发中心将要关闭。
除了Pierre Fabre，法国其他药企也面临裁员的选择。赛诺菲在自己的改组过程中也遭遇了挫折，其研发部门也被批为“产能低下”，CEO Chris Viehbacher引用了Pierre Fabre裁员的原因，同样决定裁员。
Pierre Fabre不是唯一一家面临裁员、低迷和缩减的制药公司，诺华刚刚在新泽西州销售部门裁员200人，并且仍在世界其他国家和地区继续裁员，以巩固后台运作。诺华正在经历大规模经营战略转变，将动物健康业务卖给礼来，将疫苗业务出售给葛兰素史克的肿瘤部门。与此同时，葛兰素史克也于上周宣布裁员。
百时美施贵宝上周也宣布在中国裁员1000名，不仅如此，默克也在缩减成本，最近还把消费业务出售给拜耳制药。
原文 Kiss more pharma jobs goodbye： Pierre Fabre to cut 550 in sales， R&D
Pierre Fabre hasn't had an easy time in the drug business lately. Its R&D operations have been less than productive， executives say， and sales in its home country have suffered from price cuts.
So， it's scaling back in pharma to narrow its R&D focus， build up in consumer healthcare and spend more resources on its cosmetics and dermatology businesses. The upshot？ Pierre Fabre will shrink its pharma payroll by 551 jobs by 2016. The cuts will mainly affect its French operations， with sales and R&D both in the target zone.
The larger cuts will come in R&D， which will lose 272 jobs， 255 in France， the company said in a statement. Another 279 or so will hit on the sales side. The rest will come from an R&D site in Barcelona that's slated for closure.
The job cuts aren't likely to be popular in France， where Sanofi ($SNY) ran into trouble with its own restructuring. Nor are the company's comments about its R&D operations in the country， which it called "insufficiently productive." That， too， echoes Sanofi， whose now-former CEO Chris Viehbacher cited the same reason for his French job-cutting plans in R&D.
Pierre Fabre is far from the only drugmaker cutting jobs and paring away lackluster businesses--not to mention scaling back in France. Novartis ($NVS) just cut 200 people from its New Jersey payroll in a sales-force shift， and it's cutting other jobs around the world as it consolidates back-office operations. The Swiss drugmaker is also in the midst of a wholesale strategic shift， selling its animal health business to Eli Lilly ($LLY) and swapping its vaccine business to GlaxoSmithKline ($GSK) for GSK's oncology operations. GSK announced job cuts last week as well.
Bristol-Myers Squibb ($BMY) also said last week it would hack 1，000 from its Chinese payroll. And Merck ($MRK) is cutting costs--as well as jobs--as it narrows its focus； the U.S.-based drugmaker recently sold its consumer business to Bayer.